S&P 500   4,213.99 (+0.20%)
DOW   32,977.19 (-0.35%)
QQQ   351.06 (+0.76%)
AAPL   177.31 (+1.07%)
MSFT   332.96 (+0.02%)
META   265.17 (+1.19%)
GOOGL   123.72 (-0.71%)
AMZN   121.36 (+1.04%)
TSLA   200.39 (+3.74%)
NVDA   408.96 (+5.01%)
NIO   7.65 (-0.65%)
BABA   79.23 (-2.15%)
AMD   125.61 (-1.12%)
T   15.54 (+0.26%)
F   12.59 (+4.14%)
MU   72.41 (-2.06%)
CGC   0.86 (-1.57%)
GE   101.22 (-1.48%)
DIS   87.84 (-0.51%)
AMC   4.61 (-0.65%)
PFE   37.04 (-1.49%)
PYPL   60.00 (-0.37%)
NFLX   394.36 (+4.09%)
S&P 500   4,213.99 (+0.20%)
DOW   32,977.19 (-0.35%)
QQQ   351.06 (+0.76%)
AAPL   177.31 (+1.07%)
MSFT   332.96 (+0.02%)
META   265.17 (+1.19%)
GOOGL   123.72 (-0.71%)
AMZN   121.36 (+1.04%)
TSLA   200.39 (+3.74%)
NVDA   408.96 (+5.01%)
NIO   7.65 (-0.65%)
BABA   79.23 (-2.15%)
AMD   125.61 (-1.12%)
T   15.54 (+0.26%)
F   12.59 (+4.14%)
MU   72.41 (-2.06%)
CGC   0.86 (-1.57%)
GE   101.22 (-1.48%)
DIS   87.84 (-0.51%)
AMC   4.61 (-0.65%)
PFE   37.04 (-1.49%)
PYPL   60.00 (-0.37%)
NFLX   394.36 (+4.09%)
S&P 500   4,213.99 (+0.20%)
DOW   32,977.19 (-0.35%)
QQQ   351.06 (+0.76%)
AAPL   177.31 (+1.07%)
MSFT   332.96 (+0.02%)
META   265.17 (+1.19%)
GOOGL   123.72 (-0.71%)
AMZN   121.36 (+1.04%)
TSLA   200.39 (+3.74%)
NVDA   408.96 (+5.01%)
NIO   7.65 (-0.65%)
BABA   79.23 (-2.15%)
AMD   125.61 (-1.12%)
T   15.54 (+0.26%)
F   12.59 (+4.14%)
MU   72.41 (-2.06%)
CGC   0.86 (-1.57%)
GE   101.22 (-1.48%)
DIS   87.84 (-0.51%)
AMC   4.61 (-0.65%)
PFE   37.04 (-1.49%)
PYPL   60.00 (-0.37%)
NFLX   394.36 (+4.09%)
S&P 500   4,213.99 (+0.20%)
DOW   32,977.19 (-0.35%)
QQQ   351.06 (+0.76%)
AAPL   177.31 (+1.07%)
MSFT   332.96 (+0.02%)
META   265.17 (+1.19%)
GOOGL   123.72 (-0.71%)
AMZN   121.36 (+1.04%)
TSLA   200.39 (+3.74%)
NVDA   408.96 (+5.01%)
NIO   7.65 (-0.65%)
BABA   79.23 (-2.15%)
AMD   125.61 (-1.12%)
T   15.54 (+0.26%)
F   12.59 (+4.14%)
MU   72.41 (-2.06%)
CGC   0.86 (-1.57%)
GE   101.22 (-1.48%)
DIS   87.84 (-0.51%)
AMC   4.61 (-0.65%)
PFE   37.04 (-1.49%)
PYPL   60.00 (-0.37%)
NFLX   394.36 (+4.09%)
NASDAQ:MRSN

Mersana Therapeutics (MRSN) Stock Forecast, Price & News

$7.06
-0.51 (-6.74%)
(As of 10:39 AM ET)
Compare
Today's Range
$7.01
$7.81
50-Day Range
$3.72
$8.08
52-Week Range
$2.91
$8.39
Volume
316,193 shs
Average Volume
1.56 million shs
Market Capitalization
$807.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00

Mersana Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
95.5% Upside
$14.00 Price Target
Short Interest
Healthy
5.67% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.69
Upright™ Environmental Score
News Sentiment
0.42mentions of Mersana Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$15,342 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.89) to ($1.46) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.48 out of 5 stars

Medical Sector

167th out of 1,009 stocks

Pharmaceutical Preparations Industry

65th out of 494 stocks


MRSN stock logo

About Mersana Therapeutics (NASDAQ:MRSN) Stock

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Receive MRSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRSN Stock News Headlines

Mersana Therapeutics (MRSN) Receives a Buy from SVB Securities
Is Graphite the New Lithium?
Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.
Is Graphite the New Lithium?
Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.
Mersana Therapeutics (MRSN) Gets a Buy from BTIG
See More Headlines
Receive MRSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRSN Company Calendar

Last Earnings
5/09/2023
Today
5/30/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRSN
Fax
N/A
Employees
169
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.00
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+84.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-204,210,000.00
Net Margins
-658.85%
Pretax Margin
-658.85%

Debt

Sales & Book Value

Annual Sales
$26.58 million
Book Value
$0.92 per share

Miscellaneous

Free Float
109,353,000
Market Cap
$865.93 million
Optionable
Not Optionable
Beta
1.75

Key Executives

  • Anna ProtopapasAnna Protopapas
    President, Chief Executive Officer & Director
  • Brian DeSchuytner
    Chief Financial Officer & Senior Vice President
  • Timothy B. LowingerTimothy B. Lowinger
    Chief Science & Technology Officer
  • Arvin YangArvin Yang
    Chief Medical Officer & Senior Vice President
  • Alejandra Veronica Carvajal
    Secretary, Chief Legal Officer & Senior VP













MRSN Stock - Frequently Asked Questions

Should I buy or sell Mersana Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MRSN shares.
View MRSN analyst ratings
or view top-rated stocks.

What is Mersana Therapeutics' stock price forecast for 2023?

6 brokerages have issued 1-year price objectives for Mersana Therapeutics' stock. Their MRSN share price forecasts range from $10.00 to $20.00. On average, they expect the company's stock price to reach $14.00 in the next year. This suggests a possible upside of 84.9% from the stock's current price.
View analysts price targets for MRSN
or view top-rated stocks among Wall Street analysts.

How have MRSN shares performed in 2023?

Mersana Therapeutics' stock was trading at $5.86 at the beginning of 2023. Since then, MRSN stock has increased by 29.2% and is now trading at $7.57.
View the best growth stocks for 2023 here
.

When is Mersana Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our MRSN earnings forecast
.

How were Mersana Therapeutics' earnings last quarter?

Mersana Therapeutics, Inc. (NASDAQ:MRSN) announced its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by $0.11. The company earned $7.80 million during the quarter, compared to analysts' expectations of $18.29 million. Mersana Therapeutics had a negative net margin of 658.85% and a negative trailing twelve-month return on equity of 223.97%. The business's quarterly revenue was up 290.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.59) EPS.

What is Anna Protopapas' approval rating as Mersana Therapeutics' CEO?

3 employees have rated Mersana Therapeutics Chief Executive Officer Anna Protopapas on Glassdoor.com. Anna Protopapas has an approval rating of 100% among the company's employees. This puts Anna Protopapas in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Mersana Therapeutics own?
When did Mersana Therapeutics IPO?

(MRSN) raised $75 million in an initial public offering on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Mersana Therapeutics' stock symbol?

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

Who are Mersana Therapeutics' major shareholders?

Mersana Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.85%), State Street Corp (5.61%), Sarissa Capital Management LP (3.32%), Braidwell LP (2.93%), Candriam S.C.A. (2.72%) and Baker BROS. Advisors LP (1.65%). Insiders that own company stock include Alejandra Carvajal, Andrew A F Hack, Anna Protopapas, Arvin Yang, Ashish Mandelia, Brian Deschuytner, Eva M Jack, Lawrence M Alleva, Lawrence M Alleva, Timothy B Lowinger and Tushar Misra.
View institutional ownership trends
.

How do I buy shares of Mersana Therapeutics?

Shares of MRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mersana Therapeutics' stock price today?

One share of MRSN stock can currently be purchased for approximately $7.57.

How much money does Mersana Therapeutics make?

Mersana Therapeutics (NASDAQ:MRSN) has a market capitalization of $865.93 million and generates $26.58 million in revenue each year. The company earns $-204,210,000.00 in net income (profit) each year or ($2.12) on an earnings per share basis.

How many employees does Mersana Therapeutics have?

The company employs 169 workers across the globe.

How can I contact Mersana Therapeutics?

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.mersana.com. The company can be reached via phone at (617) 498-0020 or via email at ir@mersana.com.

This page (NASDAQ:MRSN) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -